| HOME | HELP | CONTACT US | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Pediatric Oncology Branch, National Cancer Institute, Bethesda, Maryland, USA
Correspondence: Crystal L. Mackall, M.D., Pediatric Oncology Branch, National Cancer Institute, Bldg. 10, Rm. 13N240, 10 Center Dr., MSC 1928 Bethesda, Maryland 20892, USA. Telephone: 301-402-5940; Fax: 301-402-0575; e-mail: cm35c{at}nih.gov
Although cancer itself is immunosuppressive, cytotoxic antineoplastic therapy is the primary contributor to the clinical immunodeficiency observed in cancer patients. The immunodeficiency induced by cytotoxic antineoplastic therapy is primarily related to T-cell depletion, with CD4 depletion generally more severe than CD8 depletion. Myeloablative therapy, dose-intensive alkylating agents, purine nucleoside analogs, and corticosteroids substantially increase the risk of therapy-induced immunosuppression. Restoration of T-cell populations following cytotoxic antineoplastic therapy is a complex process. Efficient recovery of CD4+ T cell populations requires thymic-dependent pathways which undergo an age-dependent decline resulting in prolonged CD4+ T-cell depletion in adults following T-cell-depleting therapy. Total CD8+ T-cell numbers recover in both children and adults relatively quickly post-therapy; however, CD8+ subset disruptions often remain for a prolonged period. The clinical management of patients with therapy-induced T-cell depletion involves the maintenance of a high index of suspicion for opportunistic pathogens, irradiation of blood products, prophylaxis for viral infections, and reimmunization in selected clinical circumstances. Future research avenues include efforts to rapidly rebuild immunity following cytotoxic antineoplastic therapy so that immune-based therapies may be utilized immediately following cytotoxic therapy to target minimal residual neoplastic disease.
This article has been cited by other articles:
![]() |
C. L. Mackall, E. H. Rhee, E. J. Read, H. M. Khuu, S. F. Leitman, D. Bernstein, M. Tesso, L. M. Long, D. Grindler, M. Merino, et al. A Pilot Study of Consolidative Immunotherapy in Patients with High-Risk Pediatric Sarcomas Clin. Cancer Res., August 1, 2008; 14(15): 4850 - 4858. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Xue, M. B. Sawyer, C. J. Field, L. A. Dieleman, D. Murray, and V. E. Baracos Bolus Oral Glutamine Protects Rats against CPT-11-Induced Diarrhea and Differentially Activates Cytoprotective Mechanisms in Host Intestine but Not Tumor J. Nutr., April 1, 2008; 138(4): 740 - 746. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. M. El Saleeby, G. W. Somes, J. P. DeVincenzo, and A. H. Gaur Risk Factors for Severe Respiratory Syncytial Virus Disease in Children With Cancer: The Importance of Lymphopenia and Young Age Pediatrics, February 1, 2008; 121(2): 235 - 243. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. J. Weigel, D. A. Rodeberg, A. M. Krieg, and B. R. Blazar CpG Oligodeoxynucleotides Potentiate the Antitumor Effects of Chemotherapy or Tumor Resection in an Orthotopic Murine Model of Rhabdomyosarcoma Clin. Cancer Res., August 1, 2003; 9(8): 3105 - 3114. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Spisek, P. Chevallier, N. Morineau, N. Milpied, H. Avet-Loiseau, J.-L. Harousseau, K. Meflah, and M. Gregoire Induction of Leukemia-specific Cytotoxic Response by Cross-Presentation of Late-Apoptotic Leukemic Blasts by Autologous Dendritic Cells of Nonleukemic Origin Cancer Res., May 1, 2002; 62(10): 2861 - 2868. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | CONTACT US | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| THE ONCOLOGIST | STEM CELLS | CME | ALPHAMED PRESS JOURNALS |